New hope for rare, aggressive cancers: trial tests Immune-Boosting drug
Disease control
Recruiting now
This study is testing a new drug called tarlatamab for people with a rare and aggressive type of cancer called extrapulmonary neuroendocrine carcinoma (EPNEC). The cancer has returned or worsened after standard chemotherapy. The trial will see if tarlatamab, which works by direct…
Phase: PHASE2 • Sponsor: Inkeun Park • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC